Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update

Briefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of December 31, 2026Pivotal NEPHRO study currently exceeds 80% power for primary endpoint supporting a potential early close of enrollmentUpdated ma…